BLOG

BLOG

2026-04-09

News Update Immorna Announces First Evidence of Tissue B Cell Depletion with In Vivo CAR T JCXH 213 in Systemic Sclerosis Patient, Underscoring Platform’s Potential to Address Autoimmune Diseases

Hangzhou, CHINA – April 10, 2026 – Immorna, a clinical-stage biotechnology company pioneering next‑generation RNA therapeutics, today announced updated clinical data for JCXH‑213, its novel CD19-targeted in vivo CAR‑T candidate, demonstrating thorough B‑cell depletion in peripheral blood and lymph node tissues in a patient with Systemic Sclerosis (SSc). This marks the first reported evidence of deep tissue B‑cell depletion with an in vivo CAR‑T approach and highlights the unique capabilities of Immorna’s active‑targeting lipid complex nanoparticle (tLCNP) platform.
More +

2025-12-02

News Update Immorna Biotechnology’s Acne Therapeutic mRNA Vaccine JCXH-401 Receives US FDA Clearance to Initiate Clinical Trial

(Hangzhou, China, November 29, 2025) – Immorna Biotechnology, a biotechnology company focused on mRNA technology platforms, today announced that its investigational bivalent therapeutic mRNA vaccine candidate, JCXH-401, for the treatment of acne vulgaris, has received clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial.
More +

2025-06-12

News Update Immorna Biotherapeutics Develops Next-Generation Influenza/COVID-19 Combination mRNA Vaccine Featuring Enhanced Immunogenicity of B Influenza Antigens

The development of the mRNA-based seasonal influenza vaccines remains challenging, in part because of the relatively low immunogenicity of influenza B hemagglutinin (HA) antigens.
More +

2025-03-30

News Update Immorna Biotherapeutics Announces First Clinical Administration of JCXH-213, a Breakthrough mRNA-based In Vivo CAR Therapy

Immorna Biotherapeutics today announced the successful dosing of the first patient in its clinical study of JCXH-213, an innovative in vivo Chimeric Antigen Receptor (CAR) therapy. This milestone represents the world’s first human application of a messenger RNA (mRNA)-lipid nanoparticle (LNP)-based in vivo CAR therapy.
More +

2024-08-26

News Update Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development

Research Triangle Park, NC Aug 14, 2024 – Immorna Biotherapeutics Inc. (Immorna) today announces that it has received a grant to support the clinical development of JCXH-108 from the Bill & Melinda Gates Foundation (the foundation).
More +

2024-07-09

News Update Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors

MORRISVILLE, N.C., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein.
More +
< 123 >

Business license

Statement

SEO